Compare AEYE & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEYE | CSBR |
|---|---|---|
| Founded | 2005 | 1985 |
| Country | United States | United States |
| Employees | 116 | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.0M | 83.5M |
| IPO Year | 2011 | 2015 |
| Metric | AEYE | CSBR |
|---|---|---|
| Price | $7.24 | $6.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $14.63 | N/A |
| AVG Volume (30 Days) | ★ 122.9K | 6.1K |
| Earning Date | 05-12-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 30.56 | ★ 161.11 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,311,000.00 | $2,900,000.00 |
| Revenue This Year | $11.12 | $4.84 |
| Revenue Next Year | $11.45 | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.52 | N/A |
| 52 Week Low | $5.31 | $5.50 |
| 52 Week High | $16.39 | $9.63 |
| Indicator | AEYE | CSBR |
|---|---|---|
| Relative Strength Index (RSI) | 50.31 | 44.80 |
| Support Level | $6.50 | $5.60 |
| Resistance Level | $7.42 | $6.31 |
| Average True Range (ATR) | 0.52 | 0.25 |
| MACD | -0.07 | -0.02 |
| Stochastic Oscillator | 56.36 | 14.27 |
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences. It generates revenue through the sale of subscriptions for software-as-a-service (SaaS). accessibility solutions.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.